Financial Position - Total current assets as of June 30, 2024, are $482,645,000, a decrease from $489,600,000 as of December 31, 2023[18] - Total liabilities decreased to $778,176,000 from $873,491,000, a reduction of 10.9%[19] - The company reported total assets of $1,491,522,000 as of June 30, 2024, down from $1,512,912,000 at the end of 2023[18] - Total equity increased to $713,346,000 from $639,421,000, marking a rise of 11.5%[20] - The current portion of long-term debt decreased to $249,000 from $436,000, a decline of 42.8%[19] - As of June 30, 2024, the total debt stood at $599,741 thousand, a slight decrease from $603,790 thousand on December 31, 2023[113] Revenue and Income - Total net revenues for the three months ended June 30, 2024, were $182,394 thousand, a 25.1% increase from $145,712 thousand for the same period in 2023[21] - Net income for the three months ended June 30, 2024, was $37,949 thousand, a 45.2% increase compared to $26,124 thousand for the same period in 2023[24] - Basic net income per share for the three months ended June 30, 2024, was $0.77, up from $0.54 for the same period in 2023, indicating a 42.6% increase[21] - Total net revenues for the six months ended June 30, 2024, reached $354,230 thousand, compared to $285,734 thousand for the same period in 2023, indicating a 24.0% increase[21] - Net income for the six months ended June 30, 2024, was $81,126, compared to $52,156 for the same period in 2023, representing a 55.6% increase[29] Expenses - Operating expenses for the three months ended June 30, 2024, totaled $39,949 thousand, an increase from $35,842 thousand in the same period of 2023, reflecting an 8.6% rise[21] - Research and development expenses increased to $17,652 thousand for the three months ended June 30, 2024, up from $16,843 thousand in the same period of 2023, representing a 4.8% increase[21] - Selling, distribution, and marketing expenses increased by 34% to $9,012, primarily due to expanded marketing efforts for BAQSIMI®[186] - Research and development expenses totaled $17,652, a 5% increase from $16,843, mainly due to higher salary and personnel-related costs[187] Cash Flow - Net cash provided by operating activities increased to $124,400 for the six months ended June 30, 2024, up from $95,305 in the prior year, reflecting a 30.6% growth[29] - The company experienced a net cash used in investing activities of $54,666 for the six months ended June 30, 2024, compared to $514,915 in the previous year, indicating a substantial decrease in cash outflow[29] - The company reported a principal payment of $8,107 on long-term debt for the six months ended June 30, 2024, compared to $68,432 in the prior year, showing a significant reduction in debt repayment[29] Acquisitions and Investments - The acquisition of BAQSIMI® resulted in a cash outflow of $129,000, compared to $500,829 in the previous year, indicating a significant reduction in investment[29] - The total purchase price for the BAQSIMI® acquisition was allocated to acquired assets totaling $628.1 million, with $591.3 million attributed to BAQSIMI® product rights[60] - The Company has not triggered any sales milestones for additional contingent consideration of up to $575.0 million related to the BAQSIMI® acquisition as of June 30, 2024[61] Market and Product Performance - The company anticipates increased revenues from the newly acquired product BAQSIMI®[15] - Finished pharmaceutical products segment net revenues for the three months ended June 30, 2024, were $178.9 million, up from $142.9 million in the same period of 2023, reflecting a growth of 25.2%[83] - Sales of epinephrine surged by 47% to $54.05 million, driven by increased unit volumes due to competitor shortages[195] - The company manufactures and sells over 25 products, with major products including BAQSIMI®, Primatene MIST®, and glucagon[166] Shareholder Actions - The Company repurchased 207,288 shares for a total of $8.5 million during the three months ended June 30, 2024, compared to 3,585 shares for $0.1 million in the same period of 2023[132] - The Board of Directors authorized a $50.0 million increase to the share buyback program, bringing the total authorized amount to $335.0 million since inception[136] Tax and Regulatory - The income tax provision for the three months ended June 30, 2024, was $12,294 thousand, resulting in an effective tax rate of 24.5%, up from 19.5% in the same period of 2023[129] - The effective tax rate rose to 24% from 19%, influenced by changes in pre-tax income and timing of discrete tax items[192] Strategic Initiatives - The company is focused on expanding internationally and integrating new assets, including BAQSIMI®[15] - The FDA approved the company's Albuterol Sulfate Inhalation Aerosol in May 2024, with plans to launch in Q3 2024[169] - The company has made several strategic acquisitions to enhance its manufacturing and R&D capabilities[167] Economic Environment - Recent macroeconomic conditions, including inflation and geopolitical conflicts, pose challenges to the company's business operations[168]

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.65 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 20.51%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $0.77 per share when it actually produced earnings of $1.04, delivering a surprise of 35.06%.Over t ...

EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2024 Reports Net Revenues of $182.4 Million for the Three Months Ended June 30, 2024 RANCHO CUCAMONGA, CA – August 7, 2024 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2024. Second Quarter Highlights ● Net revenues of $182.4 million for the second quarter ● GAAP net income of $37.9 million, or $0.73 per share, for t ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Amphastar Pharmaceuticals (AMPH) , which belongs to the Zacks Medical - Generic Drugs industry, could be a great candidate to consider.When looking at the last two reports, this specialty pharmaceutical company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 18.11%, on average, in the last two quarters ...

Fundamentally, the biotechnology sphere enjoys a powerful catalyst: wealth without health means nothing. Yes, it’s important to save money and invest for the future. At the same time, investing in one’s health is even more important. You can always make more money. You can’t always gain more wellness. With that in mind, the below biotech stocks to buy on the dip are even more compelling.Again, the sector is supremely relevant. Therefore, any volatility in established or otherwise strong enterprises should e ...

TROY, Mich., June 14, 2024 /PRNewswire/ -- The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) as its "Stock to Study" and Medtronic PLC (NYSE: MDT) as its "Undervalued Stock" in the September 2024 issue for investors' informational and educational use. "With GameStop back in the headlines, the siren song of easy money has returned, luring the unschooled down treacherous paths. The National Association of Investors ...

Just_Super/E+ via Getty Images Preamble My regular readers would know I look for value, growth, and quality in the companies I write about. I have not published much lately as it has been much harder to find good quality, value investments with sustainable growth. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) surfaced using Seeking Alpha's screener is interesting. The parameters I set in Seeking Alpha's screeners were: Long-term-debt-to-total-capital (between 0% to 50%) Past 3-years average revenue gro ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 | --- | --- | |---------------------------------------------------------------------------------------------------- ...

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer Conference Call Participants Ekaterina Knyazkova - JPMorgan Timothy Chiang - Capital One Pavan Patel - Bank of America Operator Greetings and welcome to the Amphastar Pharmaceuticals' First Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-a ...

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 35.06%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $0.87 per share when it actually produced earnings of $0.88, delivering a surprise of 1.15%.Over th ...